PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33966284-2	2021	Nowadays, some of the most successful targeted radionuclide therapy (TRT) agents are 177 Lu-DOTA conjugates based on low molecular weight (LMW) Glu-ureido PSMA inhibitors.	lu-dota	89-96	folate hydrolase 1	Homo sapiens	155-159	
30763290-11	2019	Lu-DOTA-iPSMA-Lys-BN showed suitable affinity for PSMA and GRPr.	lu-dota	0-7	folate hydrolase 1	Homo sapiens	9-13	
30763290-3	2019	This study aimed to synthesize and characterize the Lu-DOTA-PSMA(inhibitor)-Lys-bombesin (Lu-DOTA-iPSMA-Lys-BN) heterodimer and to evaluate its potential to target prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPr) overexpressed in prostate cancer.	lu-dota	52-59	folate hydrolase 1	Homo sapiens	60-64	
30763290-3	2019	This study aimed to synthesize and characterize the Lu-DOTA-PSMA(inhibitor)-Lys-bombesin (Lu-DOTA-iPSMA-Lys-BN) heterodimer and to evaluate its potential to target prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPr) overexpressed in prostate cancer.	lu-dota	52-59	folate hydrolase 1	Homo sapiens	164-198	
30763290-3	2019	This study aimed to synthesize and characterize the Lu-DOTA-PSMA(inhibitor)-Lys-bombesin (Lu-DOTA-iPSMA-Lys-BN) heterodimer and to evaluate its potential to target prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPr) overexpressed in prostate cancer.	lu-dota	52-59	folate hydrolase 1	Homo sapiens	99-103